CompanyWith Siegfried as preferred partner, our customers can expect significant benefits. Bringing together our long-standing pharma and chemical heritage, we offer as an integrated supplier benefit to our customers with more synergy, expertise and value.
Explore more about how our broad range of custom development services, drug substance & drug product manufacturing capabilities, together with our existing product portfolio may help you achieve greater value.
More publications and documents are available at Downloads
About us
About us
About us
As an internationally recognized outsourcing partner, Siegfried provides products and tailor made services that integrate seamlessly into a customer’s value chain. The company offers pharmaceutical industry partners a comprehensive range of services – from development of drug substances to product development, registration and manufacturing to packaging and logistics. Once a fully integrated pharmaceutical company, Siegfried is one of the few suppliers today that can provide both the drug substance and the drug product development and production capabilities. This combination of know-how and experience is unique for a supplier of development and production services.
Siegfried has expanded its technology base and geographic presence around the world in the past years. In addition to technological competence and a global presence, full compliance for all products and work processes to ensure safety is a high priority. The company adheres to the most rigorous requirements and quality guidelines in development, production and marketing. Siegfried’s reputation in this area is confirmed by a seamless performance record for audits – carried out by regulatory authorities and clients.
Its production facilities are located in Switzerland, the USA, Malta, China, Germany, France and Spain. In 2022, the company achieved net sales of CHF 1.2 billion and currently employs more than 3600 people. Siegfried Holding AG is publicly listed on the Swiss Stock Exchange in Zurich (SIX: SFZN).
«With mastery of science and technology, we take the precious innovations of our pharmaceutical customers to industrial scale and manufacture safe drugs for patients worldwide»
Mitte
Our Vision
«Siegfried is the most trusted partner of the pharmaceutical industry and the global leader in the CDMO space – because we are the strongest team running the most competitive network»
Rechts
Our Values
Excellence «We excel in everything we do»
Passion «We deeply care about what we do and how we do it»
Integrity «We act responsibly, reliably, respectfully and live up to our own standards»
Quality «We do it right first time»
Sustainability «We do not only think about tomorrow, but far beyond»
Strategy
Strategy
Strategy
Siegfried at the end of 2015 successfully finalized the “Transform” strategy. During this phase characterized by impressive sales and earnings growth, the company became the worldwide leading supplier and service provider of chemically produced active pharmaceutical ingredients for the pharmaceutical industry and entered the business segment of sterile finished products. The follow-up strategy “Evolve” will continue the success story and the growth dynamics at a high level. The core of the “Evolve” strategy aims to reinforce Siegfried’s position as the leading integrated supplier to the pharmaceutical industry. The related key areas are targeted expansion of existing business, improved product offer along the value chain, and diversification into adjoining business segments.
Three strategic pillars for continued growth
The measures chosen to implement the “Evolve” strategy are essentially based upon three pillars:
1. An improved product range for customers is to be achieved, especially, by means of worldwide expansion into solid finished drug dosage forms (tablets, capsules). Today, Siegfried’s production in this area is based in Hal Far (Malta) and since the acquisition of the drug product manufacturing facility from Arena Pharmaceuticals GmbH in the spring 2018 as well in Zofingen (Switzerland).,The corresponding pharmaceutical development is located in Zofingen. By means of an acquisition, either in North America or in Europe, Siegfried aims to gain access to additional competitive capacity and formulation technologies. Siegfried plans to expand production capacity hand in hand with further strengthening development competencies.
2. Growth initiatives within the value chain of the existing business will make a significant contribution toward targeted growth and the expansion of critical size of sales. Siegfried focuses on the recently commenced plant expansion in Hameln, which serves the sterile filling of chemically produced APIs. The capacity includes production lines for ampoules and vials. The extensions permit technically challenging aseptic filling of sensitive bio-pharmaceutical APIs, which currently are administered to patients usually in liquid form via syringes. In view of above-average growth forecasts in this segment and the high entry barriers for competitors, Siegfried will participate in a market segment expected to remain attractive in the long run. A first step in this direction is represented by the strategic partnership with Symphogen, a Danish bio-pharmaceutical company, in terms of which Siegfried Hameln produced the first biologics last year.
3. The third pillar of “Evolve” concerns the diversification into adjoining business segments through targeted investment in technological capabilities or the acquisition of companies, giving Siegfried access to new technologies and market segments. As physical properties of APIs, for example, play a significant role in the receptivity of drugs by the human organism, we plan, in the coming years, to invest in micronization (miniaturization of drug substance particles, e.g. powder), expansion of existing competencies in spray drying (drying process used in production of powders) or lyophilization (freeze drying) of demanding APIs. Moreover, we plan to establish additional facilities for the production of highly effective substances.
History
History
History
2021 Acquisition of two pharmaceutical manufacturing sites from Novartis in Barberà del Vallès and El Masnou (Spain)
Siegfried Barbera S.L., Spain
Siegfried El Masnou, Spanien
2015 Acquisition of segments of BASF's pharmaceutical supply business in Minden (Germany), Evionnaz (Switzerland) and St. Vulbas (France)
Siegfried Evionnaz SA, Switzerland
Siegfried St. Vulbas SAS, France
Siegfried PharmaChemikalien, Germany
2014 Acquisition of a production facility for sterile filling in Hameln (Germany)
Siegfried Hameln, Germany
2013 Construction of new production sites Nantong (China) and Zofingen (Switzerland)
Nantong, China
Zofingen, Switzerland
2012 Acquisition of Alliance Medical Products (AMP) in Irvine (CA, USA)
Irvine, USA
2010 Definition of new strategy "Transform". Implementation of a new function-based organization. New investors and capital increase. Sale of the Munich (Germany) subsidiary (Pulmojet project) to Sanofi-Aventis.
2008 Sale of the pharmaceutical production site at Zofingen to Arena Pharmaceuticals
2007 Launch of a pharmaceutical production facility in Malta. Ramp up of an inhalation technology team in Munich (Germany). Sale of the Sidroga Division and the biotechnology division. Cooperation agreement with Arena Pharmaceuticals.
Hal Far, Malta
2006 Cooperation agreement with Celgene
2005 Acquisition of Penick Corporation in New Jersey (USA)
Pennsville, USA
2004 Establishment of a representative office in Shanghai (China)
2002 Integration of Gane's into Siegfried Group as Siegfried (USA) Inc.
2001 Establishment of two core divisions: Siegfried and Sidroga
1973 Listing on the Swiss Stock Exchange (SWX) in Basel
1928 Founding of Gane's Chemical Works, Inc. (NJ, USA)
Siegfried Zofingen 1920
1904 Conversion into a joint stock corporation
1873 Founding of a company with 12 employees by pharmacist Samuel Benoni Siegfried to supply pharmacies
